Regentis Biomaterials (NYSE American: RGNT) announced plans to initiate European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial launch of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The training initiative is a key step in Regentis' European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair. By expanding physician familiarity with the technology, the company aims to support adoption as the product enters broader clinical use.
According to the company, GelrinC addresses a significant unmet medical need. In the U.S. alone, approximately 470,000 cases for cartilage knee repair occur annually, where no off-the-shelf treatment is currently available. The product is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
Regentis Biomaterials Ltd is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company's lead product, GelrinC, has received CE Mark approval, enabling its commercialization in Europe.
The full press release is available at https://ibn.fm/QOWWK. For more information about Regentis Biomaterials and its technologies, interested parties can visit the company's website. Forward-looking statements in this article involve risks and uncertainties as detailed in the company's SEC filings, and undue reliance should not be placed on them.
